ISS suggest Enhabit shareholders elect three AREX Capital nominees to board
Adds quote from report in paragraph 7, updates share price in paragraph 9, adds quote from company in paragraph 11
By Svea Herbst-Bayliss
July 11 (Reuters) -Institutional Shareholder Services (ISS) said on Thursday Enhabit EHAB.N shareholders should elect three AREX Capital Management director candidates to the nine-member board, saying the company needs more expertise in home health, hospice and public company financial reporting.
The prominent proxy advisory firm, whose recommendations often guide shareholder votes on proposed mergers and who serves on a board, said AREX made a convincing case that new directors are needed.
But the hedge fund did not persuade ISS that a majority of the two-year-old company's directors should be ousted, according to thereport reviewed by Reuters.
AREX is asking investors to replace seven directors to help reverse poor financial performance. It has also been pushing the home health and hospice provider to put itself up for a sale.
Investors will vote on July 25 unless the two sides reach an agreement before the meeting date.
"The company's significant underperformance, both from a TSR (total shareholder return) and operational standpoint, indicate that a degree of change is needed at the board level," ISS wrote.
Enhabit's stock price has tumbled nearly 60% since it was spun off of post-acute healthcare services provider Encompass Health EHC.N in July 2022. The stock climbed 2.7% to close trading at$9.48 onFriday.
ISS recommended votes for AREX candidates Gregory Sheff, who has home health operations experience, Anna-Gene O'Neal, who has hospice experience, and Mark Ohlendorf, who has public company chief financial officer experience.
ISS also wrote that a more limited number of new directors could provide "effective oversight of management without implementing drastic changes that could jeopardize what appear to be the early signs of a turnaround."
Enhabit on Friday urged stockholders to vote for all its nine nominees, adding that itdisagrees with ISS's recommendation as critical experience would be lost by replacing the directors.
"We are pleased that ISS recognizes our performance over the last two quarters and agrees with the company that
shifting course now and handing control of the board to AREX is not in the best interests of the company's stockholders," Enhabit said in a statement.AREX said it is "pleased that a leading independent proxy advisory firm has recognized the lack of home health and hospice industry expertise on Enhabit's board and validated our case for meaningful boardroom change."
AREX, which owns a 4.9% stake in Enhabit, is backing CEO Barbara Jacobsmeyer and director Barry Schochet for re-election. Schochet joined the board last year when the company reached an agreement with investors Cruiser Capital and Harbour Point Capital Management in March 2023.
AREX told Enhabit last year it wanted the company to commit to immediately start a strategic review before the end of 2023. Enhabit in May decided to continue as an independent, public company after having evaluated a range of strategic options.
Reporting by Svea Herbst-Bayliss and Pratik Jain; Editing by Christian Schmollinger, Will Dunham and Arun Koyyur
Relaterade tillgångar
Senaste nytt
Ansvarsfriskrivning: XM Group-enheter tillhandahåller sin tjänst enbart för exekvering och tillgången till vår onlinehandelsplattform, som innebär att en person kan se och/eller använda tillgängligt innehåll på eller via webbplatsen, påverkar eller utökar inte detta, vilket inte heller varit avsikten. Denna tillgång och användning omfattas alltid av i) villkor, ii) riskvarningar och iii) fullständig ansvarsfriskrivning. Detta innehåll tillhandahålls därför uteslutande som allmän information. Var framför allt medveten om att innehållet på vår onlinehandelsplattform varken utgör en uppmaning eller ett erbjudande om att ingå några transaktioner på de finansiella marknaderna. Handel på alla finansiella marknader involverar en betydande risk för ditt kapital.
Allt material som publiceras på denna sida är enbart avsett för utbildnings- eller informationssyften och innehåller inte – och ska inte heller anses innehålla – rådgivning och rekommendationer om finansiella frågor, investeringsskatt eller handel, dokumentation av våra handelskurser eller ett erbjudande om, eller en uppmaning till, en transaktion i finansiella instrument eller oönskade finansiella erbjudanden som är riktade till dig.
Tredjepartsinnehåll, liksom innehåll framtaget av XM såsom synpunkter, nyheter, forskningsrön, analyser, kurser, andra uppgifter eller länkar till tredjepartssajter som återfinns på denna webbplats, tillhandahålls i befintligt skick, som allmän marknadskommentar, och utgör ingen investeringsrådgivning. I den mån som något innehåll tolkas som investeringsforskning måste det noteras och accepteras att innehållet varken har varit avsett som oberoende investeringsforskning eller har utarbetats i enlighet med de rättsliga kraven för att främja ett sådant syfte, och därför är att betrakta som marknadskommunikation enligt tillämpliga lagar och föreskrifter. Se till så att du har läst och förstått vårt meddelande om icke-oberoende investeringsforskning och riskvarning om ovannämnda information, som finns här.
